Previous studies have shown that the presence and number of distant metastases are prognostic factors for NSCLC patients treated with chemotherapy or EGFR-TKIs.[26, 35–37] Our study revealed that patients with bone metastases only had better outcomes than those who had distant metastasis at sites other than bone. This evidence concerns the gene EGFR and non-small cell lung carcinoma.